

**2126. Comparative Effectiveness of Infection Prevention Interventions for Reducing Procedure-Related Cardiac Device Infections: Insights from the VA CART Program**

Archana Asundi, MDCM<sup>1,2</sup>; Maggie Stanislawski, PhD<sup>3,4</sup>; Payal Mehta, MD<sup>2</sup> and Westyn Branch-Elliman, MD, MMSc<sup>2,5,6</sup>; <sup>1</sup>Internal Medicine, Section of Infectious Diseases, Boston University Medical Center, Boston, Massachusetts, <sup>2</sup>VA Boston Healthcare System, West Roxbury, Massachusetts, <sup>3</sup>Seattle-Denver Center of Innovation for Veteran-Centered and Value-Driven Care, Seattle, Washington, <sup>4</sup>University of Colorado School of Public Health, Denver, Colorado, <sup>5</sup>Harvard Medical School, Boston, Massachusetts, <sup>6</sup>Center for Healthcare Organization and Implementation Research, VA Boston Healthcare System, West Roxbury, Massachusetts

**Session:** 235. Healthcare Epidemiology: Surgical Site Infections  
Saturday, October 6, 2018: 12:30 PM

**Background.** Cardiovascular implantable electronic device (CIED) infections are highly morbid, thus peri-procedural prevention interventions are employed to reduce them. However, little data exists evaluating the comparative effectiveness of these prevention interventions. Thus, the objective of this study was to measure the association between infection prevention and antimicrobial prophylaxis strategies and procedure-related CIED infections among a national, multi-center cohort using a nested case-control design.

**Methods.** A selection of procedures entered into the VA Clinical Assessment Reporting and Tracking-Electrophysiology cohort from FY 2008–2016 underwent manual review for presence of infection and for type of prevention strategy used. The primary outcome was 6-month incidence of CIED infection. Measures of association were calculated using multivariable logistic regression.

**Results.** One hundred and fourteen CIED infections among 2,131 procedures were identified; 18 were superficial and 98 were deep. In a multivariable analysis, procedural factors associated with increased odds of procedure-related CIED infections included procedure complications (e.g., hematoma) and revisions (Table 1). Prevention factors associated with reduced risk included chlorhexidine (CHG) skin cleaning, pre-procedure prophylaxis with a  $\beta$ -lactam, and intra-procedure antibiotic washes. Infection prevention strategies that were not associated with risk reduction included: antibiotic mesh pockets, combination prophylaxis regimens (e.g.,  $\beta$ -lactam plus vancomycin), and prolonged antimicrobial prophylaxis lasting >24 hours post-procedure.

**Conclusion.** Although the major driver of procedure-related CIED infections are procedural factors and complications, some infection prevention strategies are beneficial. These results should be used to inform infection prevention and antimicrobial stewardship practices in the electrophysiology laboratory.

**Table 1:** Factors Associated with Risk of CIED Infection

Intervention	Odds Ratio (95% CI)	P-Value
Procedure complication	4.3 (2.6–7.2)	<0.001
Revision	2.0 (1.3–3.1)	0.002
Pre-procedure CHG	0.40 (1.3–3.1)	0.002
Pre-procedure $\beta$ -lactam	0.59 (0.38–0.72)	0.024
Antibiotic washes	0.51 (0.27–0.99)	0.045

**Disclosures.** W. Branch-Elliman, Veterans' Integrated Service Network Career Development Award; Investigator, Research grant. American Heart Association: Investigator, Research grant.

**2127. The Role of Prophylactic Antibiotics for Reducing Infections Following Knee Arthroscopy**

Nasia Safdar, MD, PhD<sup>1,2</sup>; Catherine Shaughnessy, BS<sup>1</sup>; Jackson Musuuza, MBBS, MPH, PhD<sup>1,2</sup> and Aurora Pop-Vicas, MD, MPH<sup>1</sup>; <sup>1</sup>University of Wisconsin, Madison, Wisconsin, <sup>2</sup>William S Middleton Memorial Veterans Hospital, Madison, Wisconsin

**Session:** 235. Healthcare Epidemiology: Surgical Site Infections  
Saturday, October 6, 2018: 12:30 PM

**Background.** Surgical site infections (SSI) following arthroscopy are associated with considerable morbidity. Whether antibiotic prophylaxis can reduce the risk of SSI following knee arthroscopy is unclear.

**Methods.** We undertook a meta-analysis of studies comparing incidence of SSI in patients receiving antibiotic prophylaxis vs. no antibiotics before undergoing knee arthroscopy. We searched multiple computerized databases; data were pooled using a random effects model. We excluded knee arthroscopy studies for which the distribution of patients receiving antibiotics vs. no antibiotics was unavailable. CDC definitions for SSI were used to determine incidence of infection.

**Results.** Five retrospective studies including 47,548 patients met inclusion criteria; none were randomized trials. The risk of SSI in the prophylactic antibiotic group was 0.38% and in the no antibiotic group was 0.37% (pooled OR 0.99, 95% CI 0.69–1.42). There was no statistical heterogeneity.

**Conclusion.** The evidence to date, which is limited to retrospective studies, suggests no difference in SSI incidence with and without antibiotic prophylaxis for knee arthroscopies. Prospective studies are required to further evaluate this finding. Future research should evaluate whether antibiotic prophylaxis prevents SSI in other joint arthroscopy procedures, such as shoulder arthroscopy.

**Disclosures.** All authors: No reported disclosures.

**2128. Predictors of Post-Discharge Prophylactic Antibiotics Following Spinal Fusion**

David K. Warren, MD, MPH, FIDSA, FSHEA<sup>1</sup>; Katelyn B. Nickel, MPH<sup>1</sup>; Ian Banks, pre-BA<sup>1</sup>; Jennifer H. Han, MD, MSCE<sup>2,3</sup>; Pam Tolomeo, MPH<sup>3</sup>; Christopher Hostler, MD, MPH<sup>4</sup>; Katherine Foy, RN<sup>5</sup>; Victoria Fraser, MD, FIDSA, FSHEA<sup>2</sup>; Margaret A. Olsen, PhD, MPH<sup>1,6</sup> and for the CDC Prevention Epicenter Program; <sup>1</sup>Division of Infectious Diseases, Washington University School of Medicine, St. Louis, Missouri, <sup>2</sup>Division of Infectious Diseases, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, <sup>3</sup>Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, <sup>4</sup>Duke Center for Antimicrobial Stewardship and Infection Prevention, Durham, North Carolina, <sup>5</sup>Department of Medicine, Washington University School of Medicine, Saint Louis, Missouri, <sup>6</sup>Department of Medicine, Division of Infectious Diseases, Washington University School of Medicine, St. Louis, Missouri

**Session:** 235. Healthcare Epidemiology: Surgical Site Infections  
Saturday, October 6, 2018: 12:30 PM

**Background.** Discontinuation of prophylactic antibiotics <24 hours after surgery is recommended in multiple guidelines, but prophylactic antibiotics are still prescribed at discharge for some procedures. The objective of this study was to determine the prevalence and predictors of post-discharge prophylactic antibiotic use after spinal fusion.

**Methods.** We established a retrospective cohort of patients aged  $\geq 18$  years undergoing spinal fusion between July 2010 and June 2015 at three teaching hospitals. We excluded patients with infections during the spinal fusion admission. Prophylactic antibiotics were identified at discharge.

**Results.** A total of 9,690 spinal fusion admissions were identified. The median age of patients was 57 years; 4,425 (45.7%) were male; 1,070 (11.0%) were trauma patients; and 352 (3.6%) had underlying malignancy. Antibiotic(s) were prescribed at discharge in 381 (3.9%) admissions. The most commonly prescribed antibiotics were trimethoprim/sulfamethoxazole (23.4%), ciprofloxacin (16.4%) and cephalixin (16.1%). Independent predictors of prophylactic discharge antibiotics are shown in the table.

**Conclusion.** Post-discharge prophylactic antibiotics were uncommon after spinal fusion. Factors associated with use included hospital, trauma, prolonged surgery time, intra-operative antibiotics, plus patient factors, including obesity, malignancy, fluid and electrolyte disorders, valvular heart disease and high American Society of Anesthesiologists (ASA) score.

Risk Factor	Odds Ratio (95% Confidence Interval)
Hospital	
1	Referent
2	2.49 (1.83, 3.41)
3	1.79 (1.36, 2.35)
Morbid obesity	1.64 (1.15, 2.36)
Hypothyroidism	1.34 (0.96, 1.87)
Fluid and electrolyte disorders	1.53 (1.13, 2.07)
Paralysis	1.71 (0.97, 2.98)
Valvular heart disease	1.83 (1.14, 2.95)
Malignancy	2.03 (1.37, 3.01)
ASA score $\geq 3$	1.42 (1.13, 1.78)
Hematoma/seroma	2.40 (0.99, 5.83)
Trauma patient	1.76 (1.33, 2.33)
Cervical spinal fusion	0.78 (0.62, 1.00)
Thoracic spinal fusion	1.29 (0.97, 1.70)
Intraoperative IV antibiotics	
Cefazolin or clindamycin	Referent
Vancomycin	1.52 (1.02, 2.28)
Other IV antibiotic or >1 IV antibiotic	1.55 (1.18, 2.02)
None	3.11 (1.85, 5.25)
Surgery time $\geq 90$ minutes	1.81 (1.10, 2.97)

**Disclosures.** All authors: No reported disclosures.

**2129. Utilization of Post-Discharge Antibiotics in Spinal Fusion in a Nationwide Cohort of Commercially Insured Individuals**

David K. Warren, MD, MPH, FIDSA, FSHEA<sup>1</sup>; Kate Peacock, MPH<sup>1</sup>; Katelyn B. Nickel, MPH<sup>1</sup>; Victoria Fraser, MD, FIDSA, FSHEA<sup>2</sup>; Margaret A. Olsen, PhD, MPH<sup>1</sup> and the CDC Prevention Epicenter Program; <sup>1</sup>Division of Infectious Diseases, Washington University School of Medicine, St. Louis, Missouri, <sup>2</sup>Department of Medicine, Washington University School of Medicine, Saint Louis, Missouri

**Session:** 235. Healthcare Epidemiology: Surgical Site Infections  
Saturday, October 6, 2018: 12:30 PM

**Background.** Discontinuation of prophylactic antibiotics within 24 hours after surgery is recommended in multiple guidelines. The objective of this study was to determine the prevalence and patterns of prophylactic post-discharge antibiotic use after spinal fusion in a geographically representative, privately insured population.

**Methods.** We established a cohort of patients aged 10–64 years undergoing inpatient or ambulatory surgery spinal fusion between January 1, 2010–June 30, 2015 using the Truven Health MarketScan Database. Antibiotics were identified from outpatient drug claims  $\leq 5$  days post-discharge; comorbidities were assessed  $\leq 1$  year before surgery. Patients with infection during the surgical admission or  $\leq 30$  days prior were